课题基金 / 基金详情

Targeting TSLP - Novel anti-inflammatory compounds for the treatment and prevention of atopic diseases

Targeting TSLP - Novel anti-inflammatory compounds for the treatment and prevention of atopic diseases
靶向 TSLP - 用于治疗和预防特应性疾病的新型抗炎化合物
批准号：
419584
负责人：
Hedtrich Sarah
金额：
$58.52万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
未结题
起止时间：
2020-03-01 至 2025-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=419584&lang=en
关键词：
Atopic Diseases Drug Discovery And Development Inflammatory Skin Diseases New Anti-Inflammatory Drugs Topical Drug Delivery Tslp Inhibitors

项目摘要

项目成果

Hedtrich Sarah的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Atopic dermatitis (AD) is one of the most common inflammatory skin diseases and up to 17% of the Canadian population is affected at some point in their lives. Furthermore, AD often is an entry point for further allergies such as food allergies, hay fever
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Correcting monogenic skin diseases in situ: Assessing the potential of topically applicable gene therapy.
  • 批准号：
    400904
  • 项目类别：
    Operating Grants
  • 资助金额：
    $34.44万
  • 财政年份：
    2019
  • 负责人：
    Hedtrich Sarah
  • 依托单位：
    University of British Columbia
海外基金